Real-world assessment of afatinib for patients with EGFR-positive non-small cell lung cancer-Reference-Cited by-同舟云学术

Real-world assessment of afatinib for patients with EGFR-positive non-small cell lung cancer

Published:2020-05-15 Issue:6 Volume:38 Page:1906-1914
ISSN:0167-6997
Container-title:Investigational New Drugs
language:en
Short-container-title:Invest New Drugs

Author:

Igawa Satoshi,Ono Taihei,Kasajima Masashi,Kusuhara Seiichiro,Otani Sakiko,Fukui Tomoya,Yokoba Masanori,Kubota Masaru,Katagiri Masato,Mitsufuji Hisashi,Sasaki Jiichiro,Naoki Katsuhiko

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s10637-020-00948-9.pdf

Reference32 articles.

1. Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Allen C et al (2017) Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA Oncol 3:524–548. https://doi.org/10.1001/jamaoncol.2016.5688

2. Siegel R, DeSantis C, Virgo K et al (2012) Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 62:220–241. https://doi.org/10.3322/caac.21149

3. Bria E, Milella M, Cuppone F et al (2011) Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line treatment: a meta-analysis. Ann Oncol 22:2277–2285. https://doi.org/10.1093/annonc/mdq742

4. Petrelli F, Borgonovo K, Cabiddu M, Barni S (2012) Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non–small-cell lung cancer: a meta-analysis of 13 randomized trials. Clin Lung Cancer 13:107–114. https://doi.org/10.1016/j.cllc.2011.08.005

5. Paez JG, Jänne PA, Lee JC et al (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497–1500. https://doi.org/10.1126/science.1099314

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Values of circulating tumor DNA for non-small cell lung cancer patients receiving neoadjuvant therapy, progress and challenges: a narrative review;Journal of Thoracic Disease;2024-07

2. The Glasgow Prognostic Score Predicts Survival in Patients with Advanced Non-Small Cell Lung Cancer Harboring Sensitive Epidermal Growth Factor Receptor Mutations Who Are Treated with Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors;Oncology;2023

3. The Glasgow prognostic score predicts survival in patients with advanced non-small cell lung cancer harboring sensitive EGFR mutations who are treated with tyrosine kinase inhibitors;2022-11-15

4. Real-world data with afatinib in Spanish patients with treatment-naïve non-small-cell lung cancer harboring exon 19 deletions in epidermal growth factor receptor (Del19 EGFR): Clinical experience of the Galician Lung Cancer Group;Cancer Treatment and Research Communications;2022

5. Efficacy and Safety of Afatinib in the Treatment of Advanced Non-Small-Cell Lung Cancer with EGFR Mutations: A Meta-Analysis of Real-World Evidence;Journal of Oncology;2021-12-18